Barclays PLC Buys 30,093 Shares of Sera Prognostics, Inc. (NASDAQ:SERA)

Barclays PLC grew its holdings in shares of Sera Prognostics, Inc. (NASDAQ:SERA) by 321.6% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 39,450 shares of the company’s stock after buying an additional 30,093 shares during the period. Barclays PLC owned 0.12% of Sera Prognostics worth $308,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Jane Street Group LLC boosted its stake in Sera Prognostics by 24.8% during the third quarter. Jane Street Group LLC now owns 14,225 shares of the company’s stock worth $111,000 after acquiring an additional 2,826 shares in the last quarter. State Street Corp increased its holdings in Sera Prognostics by 8.8% in the 3rd quarter. State Street Corp now owns 425,093 shares of the company’s stock worth $3,316,000 after acquiring an additional 34,479 shares in the last quarter. MetLife Investment Management LLC increased its stake in Sera Prognostics by 129.1% in the 3rd quarter. MetLife Investment Management LLC now owns 17,254 shares of the company’s stock worth $135,000 after buying an additional 9,722 shares in the last quarter. Quest Partners LLC boosted its position in shares of Sera Prognostics by 533.5% during the third quarter. Quest Partners LLC now owns 6,430 shares of the company’s stock worth $50,000 after acquiring an additional 5,415 shares during the last quarter. Finally, Prime Capital Investment Advisors LLC bought a new stake in shares of Sera Prognostics in the third quarter worth about $104,000. 54.64% of the stock is owned by institutional investors.

Insider Buying and Selling

In other news, insider Paul Kearney sold 4,078 shares of the company’s stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total value of $29,850.96. Following the transaction, the insider now directly owns 176,889 shares in the company, valued at approximately $1,294,827.48. This represents a 2.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CEO Zhenya Lindgardt sold 12,075 shares of Sera Prognostics stock in a transaction dated Monday, November 11th. The shares were sold at an average price of $7.32, for a total transaction of $88,389.00. Following the sale, the chief executive officer now owns 819,758 shares of the company’s stock, valued at $6,000,628.56. The trade was a 1.45 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 28,250 shares of company stock valued at $206,774 in the last ninety days. 15.80% of the stock is owned by company insiders.

Sera Prognostics Stock Down 3.7 %

Sera Prognostics stock opened at $8.02 on Friday. Sera Prognostics, Inc. has a 52-week low of $4.90 and a 52-week high of $12.35. The firm’s fifty day moving average is $7.47 and its 200 day moving average is $7.25. The company has a market cap of $270.85 million, a price-to-earnings ratio of -8.10 and a beta of 0.92.

Sera Prognostics (NASDAQ:SERA) last posted its quarterly earnings data on Wednesday, November 6th. The company reported ($0.24) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.22) by ($0.02). The business had revenue of $0.03 million for the quarter, compared to analyst estimates of $0.09 million. During the same quarter last year, the business earned ($0.23) EPS. On average, equities research analysts anticipate that Sera Prognostics, Inc. will post -0.96 earnings per share for the current fiscal year.

About Sera Prognostics

Sera Prognostics, Inc, a women's health diagnostic company, discovers, develops, and commercializes biomarker tests for improving pregnancy outcomes in the United States. The company develops PreTRM test, a blood-based biomarker test to predict the risk of spontaneous preterm birth in singleton pregnancies.